Background: Immune-checkpoint inhibitors (ICIs) have increased and improved the treatment options for patients with non-oncogene-addicted advanced stage non-small cell lung cancer (NSCLC). However, the role of ICIs in oncogene-addicted advanced stage NSCLC patients is still debated. In this study, in an attempt to fill in the informational gap on the effect of ICIs on other driver mutations, we set out to provide a molecular landscape of clinically relevant oncogenic drivers in programmed death-ligand 1 (PD-L1) positive NSCLC patients. Methods: We retrospectively reviewed data on 167 advanced stage NSCLC PD-L1 positive patients (≥1%) who were referred to our clinic for molecular evaluation of five driver oncogenes, namely, EGFR, KRAS, BRAF, ALK and ROS1. Results: Interestingly, n = 93 (55.7%) patients showed at least one genomic alteration within the tested genes. Furthermore, analyzing a subset of patients with PD-L1 tumor proportion score (TPS) ≥ 50% and concomitant gene alterations (n = 8), we found that n = 3 (37.5%) of these patients feature clinical benefit with ICIs administration, despite the presence of a concomitant KRAS gene alteration. Conclusions: In this study, we provide a molecular landscape of clinically relevant biomarkers in NSCLC PD-L1 positive patients, along with data evidencing the clinical benefit of ICIs in patient NSCLC PD-L1 positive alterations.

Pisapia, P., Iaccarino, A., De Luca, C., Acanfora, G., Bellevicine, C., Bianco, R., et al. (2022). Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23(15) [10.3390/ijms23158541].

Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy

Pagni, Fabio;Seminati, Davide;
2022

Abstract

Background: Immune-checkpoint inhibitors (ICIs) have increased and improved the treatment options for patients with non-oncogene-addicted advanced stage non-small cell lung cancer (NSCLC). However, the role of ICIs in oncogene-addicted advanced stage NSCLC patients is still debated. In this study, in an attempt to fill in the informational gap on the effect of ICIs on other driver mutations, we set out to provide a molecular landscape of clinically relevant oncogenic drivers in programmed death-ligand 1 (PD-L1) positive NSCLC patients. Methods: We retrospectively reviewed data on 167 advanced stage NSCLC PD-L1 positive patients (≥1%) who were referred to our clinic for molecular evaluation of five driver oncogenes, namely, EGFR, KRAS, BRAF, ALK and ROS1. Results: Interestingly, n = 93 (55.7%) patients showed at least one genomic alteration within the tested genes. Furthermore, analyzing a subset of patients with PD-L1 tumor proportion score (TPS) ≥ 50% and concomitant gene alterations (n = 8), we found that n = 3 (37.5%) of these patients feature clinical benefit with ICIs administration, despite the presence of a concomitant KRAS gene alteration. Conclusions: In this study, we provide a molecular landscape of clinically relevant biomarkers in NSCLC PD-L1 positive patients, along with data evidencing the clinical benefit of ICIs in patient NSCLC PD-L1 positive alterations.
No
Articolo in rivista - Articolo scientifico
Scientifica
molecular oncology; molecular pathology; PD-L1; immune-checkpoint inhibitors; biomarkers
English
Special Issue "State-of-the-Art Molecular Oncology in Italy"
Pisapia, P., Iaccarino, A., De Luca, C., Acanfora, G., Bellevicine, C., Bianco, R., et al. (2022). Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23(15) [10.3390/ijms23158541].
Pisapia, P; Iaccarino, A; De Luca, C; Acanfora, G; Bellevicine, C; Bianco, R; Daniele, B; Ciampi, L; De Felice, M; Fabozzi, T; Formisano, L; Giordano, P; Gridelli, C; Ianniello, G; Libroia, A; Maione, P; Nacchio, M; Pagni, F; Palmieri, G; Pepe, F; Russo, G; Salatiello, M; Santaniello, A; Scamarcio, R; Seminati, D; Troia, M; Troncone, G; Vigliar, E; Malapelle, U
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/390286
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
Social impact